Primary Central Nervous System Lymphoma Clinical Trial
Official title:
A Phase I/II Study of Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma. This is the first study to examine a naked anti-CD19 monoclonal antibody in relapsed CNS lymphoma patients as well as the combination of anti-CD19 antibody plus an Immunomodulatory imide drugs (IMiDs) in CNS lymphomas. This study will also test the novel hypothesis that Tafasitamab enhances blood-brain barrier permeability, a potential property that could have broad clinical implications.
PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of lenalidomide in combination with Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma (Phase 1). II. To evaluate the clinical benefit rate of Tafasitamab in combination with lenalidomide in relapsed CNS lymphoma (Phase 2). SECONDARY OBJECTIVES: I. To describe the toxicities of Tafasitamab in combination with lenalidomide in relapsed CNS lymphoma. II. To describe the efficacy of Tafasitamab in combination with lenalidomide in relapsed CNS lymphoma. EXPLORATORY OBJECTIVES: I. To obtain pilot information about cerebral spinal fluid (CSF) penetration of Tafasitamab as well as CSF partition coefficient of lenalidomide in combination with Tafasitamab to evaluate possibility that Tafasitamab enhances CSF penetration of lenalidomide to an extent greater than CSF/plasma partition coefficient of lenalidomide which was 20% at 15 and 20 milligram (mg) dose levels. II. To evaluate the relationship between tumor mutational profile and response to Tafasitamab plus lenalidomide, via whole exome sequencing of diagnostic specimens. II. To evaluate change in immune cell phenotypes in CSF and blood in patients via flow-cytometry of natural killer (NK) cell, T-cells and CSF monocytes/macrophages in patients treated with combination Tafasitamab plus lenalidomide. IV. To evaluate the relationship between CSF cytokine microenvironment such as Interleukin-10 (IL-10), Chemokine ligand 13 (CXCL13), etc. as well as CSF metabolites, including energy metabolites and neurotransmitters, and response to combination Tafasitamab plus lenalidomide Tafasitamab, PFS, OS, and neurocognitive endpoints. V. To test the hypothesis that Tafasitamab in combination with lenalidomide impacts blood-brain barrier permeability associated with CNS lymphoma lesions, as assessed by albumin levels and MRI vascular permeability imaging metrics. VI. To explore the correlation between immune cell subsets and response and/or resistance to lenalidomide/Tafasitamab. VII. To evaluate the relationship between Minimal Residual Disease status (MRD) and response and PFS using either circulating tumor DNA or Clonoseq technologies. STUDY DESIGN: This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed CNS lymphoma.During the phase 1 portion of the study, the investigators will examine three dose levels of Lenalidomide (10mg, 15mg and 20mg) in combination with Tafasitamab at a dose of 12 mg/kg. After MTD/RP2D is determined during phase 1, the phase 2 portion of the study will begin enrollment to the established dose. Participants will be followed for AEs 90 days after last dose/decision to discontinue treatment, or new treatments are administered and followed for overall survival/disease status for up to 1 year after last dose. Participants may continue study treatment until disease progression. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04083066 -
Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma
|
Phase 4 | |
| Recruiting |
NCT05681195 -
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
|
Phase 2 | |
| Active, not recruiting |
NCT02313389 -
Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma
|
Phase 3 | |
| Recruiting |
NCT02836158 -
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02657785 -
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05135858 -
Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma
|
Phase 1 | |
| Completed |
NCT01421524 -
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
|
Phase 1 | |
| Active, not recruiting |
NCT00863460 -
Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients
|
Phase 2 | |
| Active, not recruiting |
NCT05036577 -
A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
|
Phase 1 | |
| Recruiting |
NCT04514393 -
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT04066920 -
IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL
|
Phase 2 | |
| Recruiting |
NCT03733327 -
BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT
|
Phase 2/Phase 3 | |
| Recruiting |
NCT00455286 -
a Phase II Study in Primary Central Nervous System Lymphoma
|
Phase 2 | |
| Completed |
NCT02301364 -
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
|
Phase 2 | |
| Completed |
NCT00112593 -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
N/A | |
| Completed |
NCT02669511 -
PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT04457869 -
A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
|
Phase 2 | |
| Recruiting |
NCT02655744 -
Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute
|
||
| Recruiting |
NCT02399189 -
MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04831658 -
A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma
|
Phase 1/Phase 2 |